re.Mind Capital

Motif Neurotech is a company focused on developing minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. Through its innovative approach, the company specializes in wireless power and data transmission, which facilitates the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. This technology enables patients to potentially repair neural circuits using minimally invasive electronic therapies, offering hope for more effective treatment options for those struggling with mental health challenges.

Precision Neuroscience, founded in 2021 and based in New York, develops next-generation brain-computer interface technology aimed at treating neurological illnesses. The company's platform is designed to be minimally invasive and safely removable, with the capability to process large amounts of data. This technology enables direct connection between the human brain and artificial intelligence, offering potential breakthrough treatments for the one billion patients worldwide affected by neurological conditions.

Sensorium Therapeutics is a Boston-based drug discovery platform founded in 2021 that focuses on developing innovative FDA-approved psychoactive medicines. The company leverages an artificial intelligence product engine to discover and develop treatments for central nervous system diseases. By integrating historical human efficacy data of natural compounds, Sensorium Therapeutics aims to create new medicines characterized by unique pharmacological profiles and improved clinical success rates. This approach enhances the drug development processes for pharmaceutical companies, positioning Sensorium Therapeutics as a key player in the advancement of therapeutic solutions.

iLoF, or Intelligent Lab on Fiber, is a technology company specializing in the integration of photonics and artificial intelligence to enhance drug discovery and development. The company has developed a patented system that identifies and captures unique features of gold-standard biomarkers, creating a cloud-based digital library of these biological profiles. This platform allows for the collection of extensive data, which facilitates personalized medicine by enabling healthcare companies to conduct more efficient and patient-centric clinical trials. By employing a multidisciplinary approach that involves physicists, biologists, and data scientists, iLoF aims to accelerate the development of tailored treatments, ultimately improving patient outcomes and reducing the costs associated with drug development.

Alena is a healthcare application developer that utilizes neuroscience-based games to evaluate user behavior and identify thinking patterns linked to mental health disorders. Founded in 2019 in London, the company combines insights from computational neuroscience and psychiatry to enhance user understanding and treatment options. Its application offers a unique approach that merges evidence-based therapy with innovative techniques to address social anxiety and other mental health challenges. By dynamically adapting to users' evolving needs, Alena aims to facilitate effective stress management and help users overcome anxiety, thereby improving overall mental well-being.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

OccamzRazor is a biotechnology company that leverages machine learning and advanced biological techniques to enhance drug discovery and development processes. The company employs two proprietary technologies: Panoramic AI and RazorBrain. These tools work together to extract data from unstructured text sources, such as publications and patient-reported outcomes, and integrate it with structured data like genomics, proteomics, and phenomics. This integration aims to generate robust hypotheses for drug discovery and provide valuable insights into therapeutic strategies. OccamzRazor's applications include extracting and curating biomedical text data, identifying novel targets, and repurposing existing drugs. The company is particularly focused on developing neuroscience therapeutics, with a notable emphasis on Parkinson's Disease.

CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company focuses on developing a computer-brain interface (CBI) technology that enhances the programming of neuromodulation systems. This innovative platform allows for the direct transmission of information into human consciousness, utilizing existing neuromodulation implants to improve medical treatments. CereGate's technology aims to support patients with neurological disorders or sensory deficits by providing new therapeutic options that enable them to adapt and enhance their conditions independently. The company's approach encompasses a broad range of applications, from sensory substitution to gait improvement.

OpenBCI is a developer of an open-source brain-computer interface designed to democratize access to neurotechnology and biosensing tools. The company provides a low-cost, programmable platform that allows users to interface with brain signals through electroencephalography (EEG) and other biosensing systems, including electromyography (EMG) and electrocardiography (EKG). By leveraging a collaborative community of scientists, engineers, and makers, OpenBCI aims to foster innovation in brain science and neuroscience research. Unlike traditional BCI companies that offer proprietary devices with limited access to their underlying algorithms, OpenBCI's open-source approach empowers users at all skill levels to engage in research and development, making it an ideal resource for those exploring the rapidly evolving field of brain-computer interfacing. The platform serves as a flexible foundation for experimentation, enabling researchers to customize hardware setups and signal processing techniques to suit their specific needs.

Kanna Health is a preclinical stage biotechnology company focused on developing innovative therapeutics derived from kanna, or Sceletium tortuosum, a medicinal succulent historically utilized by the San hunter-gatherers of South Africa. The company aims to address significant unmet needs in sexual and mental health through its lead candidate, KH-001, which is formulated from alkaloids found in kanna. This candidate is designed to enhance mood and performance in males, offering potential for affordable treatment options. Kanna Health's mission centers on leveraging the traditional use of kanna to create modern therapeutic solutions that improve health outcomes.

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Tripp Inc. is a company focused on developing a digital psychedelic wellness platform that utilizes virtual and augmented reality to enhance emotional well-being. Founded in 2016 and headquartered in Los Angeles, California, with a satellite office in Chicago, the company creates immersive experiences that combine audio, visual elements, and gameplay mechanics to promote mindfulness and transformation. Tripp’s offerings are informed by scientific research indicating that interactive digital experiences can positively influence brain function. Through its platform, the company delivers wellness solutions designed to help users manage their emotions, reduce stress and anxiety, and achieve a state of calm and focus.

Ksana Health, founded in 2019 and based in Eugene, Oregon, is a developer of a digital mental health platform that aims to enhance mental health outcomes through personalized behavioral insights and timely interventions. The company's platform enables the collection of mental health data from users, which is then seamlessly transferred to healthcare practitioners via an app. By providing passive and continuous remote patient monitoring alongside digital therapeutics, Ksana Health seeks to support individuals in managing their mental health effectively.

Synchron is a medical technology company focused on developing innovative brain-computer interface solutions. It manufactures an implantable device known as the stentrode, which is delivered to the brain via a catheter. This minimally invasive device is embedded with electrode arrays that can interpret neuronal signals and modulate neural activity in targeted areas. By enabling patients with motor impairments to control digital devices, prosthetics, and other assistive technologies through thought, Synchron aims to enhance the quality of life for individuals with disabilities.

Blackrock Neurotech is a company dedicated to developing advanced neurotechnology platforms designed to record bio-potentials from both the central and peripheral nervous systems for chronic and acute applications. The company's precision electrode technology is pivotal in numerous global innovations related to brain-computer interfaces (BCI) and neural signal processing and stimulation. Blackrock Neurotech aims to assist individuals with disabilities, enabling them to walk, talk, see, hear, and feel by providing the clinical community with innovative tools and expertise to create novel implantable solutions that enhance human lives.

CB Therapeutics is a biotechnology company focused on the biosynthetic production of cannabinoids and tryptamines using a cellular agriculture platform. By employing yeast and sugar as raw materials, the company produces pure cannabinoids such as CBD and THC, eliminating the need for plant cultivation. This innovative approach allows CB Therapeutics to develop cannabinoids and their analogs for the treatment of various diseases, particularly those related to mental health. The company's efforts aim to advance clinical research and contribute to addressing serious health conditions, ultimately enhancing healthspan and improving patient outcomes in the healthcare industry.